X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (887) 887
immunotherapy (510) 510
oncology (504) 504
humans (470) 470
immune-related adverse events (457) 457
nivolumab (444) 444
ipilimumab (334) 334
immunology (326) 326
melanoma (289) 289
cancer (282) 282
animals (251) 251
pembrolizumab (248) 248
male (236) 236
immune-related genes (220) 220
female (218) 218
immune checkpoint inhibitors (200) 200
aged (182) 182
immune-related adverse event (177) 177
middle aged (173) 173
fisheries (172) 172
adverse events (163) 163
patients (163) 163
analysis (151) 151
gene expression (150) 150
marine & freshwater biology (146) 146
metastatic melanoma (143) 143
metastasis (140) 140
therapy (138) 138
care and treatment (137) 137
chemotherapy (134) 134
immune-related response (129) 129
expression (123) 123
lung cancer (121) 121
case report (117) 117
veterinary sciences (115) 115
advanced melanoma (114) 114
adult (113) 113
genes (113) 113
immune checkpoint inhibitor (112) 112
docetaxel (110) 110
immune checkpoint (106) 106
open-label (105) 105
antibodies, monoclonal - adverse effects (103) 103
research (101) 101
immune response (99) 99
pd-1 (99) 99
cancer therapies (96) 96
immunotherapy - adverse effects (96) 96
survival (95) 95
complications and side effects (92) 92
antineoplastic agents, immunological - adverse effects (90) 90
checkpoint inhibitors (89) 89
immune system (88) 88
management (88) 88
treatment outcome (88) 88
blockade (87) 87
programmed cell death 1 receptor - antagonists & inhibitors (87) 87
apoptosis (84) 84
safety (83) 83
aged, 80 and over (82) 82
antibodies, monoclonal - therapeutic use (81) 81
health aspects (81) 81
cell lung-cancer (79) 79
tumors (79) 79
anti-pd-1 (78) 78
lung neoplasms - drug therapy (77) 77
lymphocytes (77) 77
medicine, research & experimental (75) 75
melanoma - drug therapy (75) 75
immunotherapy - methods (74) 74
pharmacology & pharmacy (74) 74
toxicity (73) 73
antibodies (70) 70
antineoplastic agents - adverse effects (67) 67
review (64) 64
antigens (63) 63
autoimmunity (63) 63
proteins (63) 63
risk factors (62) 62
usage (62) 62
antineoplastic agents - therapeutic use (61) 61
fish (61) 61
genetic research (61) 61
colitis (60) 60
neoplasms - drug therapy (60) 60
neoplasms. tumors. oncology. including cancer and carcinogens (60) 60
immune‐related adverse events (59) 59
innate immunity (59) 59
solid tumors (59) 59
immune related adverse events (58) 58
prognosis (58) 58
respiratory system (58) 58
antibodies, monoclonal, humanized - adverse effects (57) 57
antineoplastic agents, immunological - therapeutic use (57) 57
drug therapy (57) 57
clinical trials (56) 56
biomarkers (55) 55
cells (55) 55
ctla-4 (55) 55
medicine & public health (55) 55
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1524) 1524
Japanese (26) 26
Chinese (18) 18
French (16) 16
German (8) 8
Korean (8) 8
Spanish (3) 3
Hungarian (1) 1
Italian (1) 1
Portuguese (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Critical Reviews in Oncology / Hematology, ISSN 1040-8428, 12/2017, Volume 120, pp. 13 - 21
Manipulating an individual’s immune system through immune checkpoint blockade is revolutionizing the paradigms of cancer treatment. Peculiar patterns and... 
Immune related response criteria | Pseudoprogression | Imaging | Immunotherapy | ASSESSMENT CRITERIA | TUMOR MEASUREMENTS | IMMUNE-RELATED RESPONSE | MONOCLONAL-ANTIBODY | COMPUTED-TOMOGRAPHY | METASTATIC MELANOMA | CHECKPOINT INHIBITORS | POSITRON-EMISSION-TOMOGRAPHY | ONCOLOGY | SQUAMOUS-CELL CARCINOMA | HEMATOLOGY | ADVERSE EVENTS
Journal Article
The Oncologist, ISSN 1083-7159, 06/2017, Volume 22, Issue 6, pp. 709 - 718
Journal Article
The Oncologist, ISSN 1083-7159, 08/2018, Volume 23, Issue 8, pp. 874 - 878
Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for cancer. Due to the mechanism of action of ICIs, inflammatory reactions against... 
Myocarditis | Immune checkpoint inhibitor | Project Data Sphere | PD‐1/PD‐L1 inhibitor | Immune‐related adverse events | Immune-related adverse events | PD-1/PD-L1 inhibitor | MANAGEMENT | FATAL MYOCARDITIS | THERAPY | PEMBROLIZUMAB | ONCOLOGY | PD-L1 inhibitor | PATIENT | NIVOLUMAB | PD-1 | IPILIMUMAB | FULMINANT MYOCARDITIS | PD‐L1 inhibitor | Commentaries | PD‐1
Journal Article
FRONTIERS IN PHARMACOLOGY, ISSN 1663-9812, 04/2019, Volume 10, p. 454
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 12/2018, Volume 13, Issue 12, pp. 1930 - 1939
Checkpoint inhibitor pneumonitis (CIP) is an immune-related adverse event that can occur after initiation of anti–programmed death 1/programmed death ligand 1... 
Checkpoint inhibitor pneumonitis | Checkpoint inhibitors | Immune-related adverse events | NSCLC | Immunotherapy | PEMBROLIZUMAB | ONCOLOGY | RESPIRATORY SYSTEM | INHIBITORS | NIVOLUMAB | DOCETAXEL | ADVERSE EVENTS
Journal Article
Chest, ISSN 0012-3692, 08/2017, Volume 152, Issue 2, pp. 271 - 281
Programmed death 1 (PD-1) programmed death-ligand 1 (PD-L1) inhibitors show significant clinical activity in non-small cell lung carcinoma (NSCLC). However,... 
non-small cell lung cancer | meta-analysis | pneumonitis | immune-related adverse events | immunotherapy | 1ST-LINE TREATMENT | SAFETY | PHASE-II | OPEN-LABEL | ATEZOLIZUMAB | DOCETAXEL | TRIAL | ANTI-PD-L1 ANTIBODY | RESPIRATORY SYSTEM | NIVOLUMAB | AVELUMAB MSB0010718C | CRITICAL CARE MEDICINE
Journal Article